哈药股份 (600664)

Harbin Pharmaceutical Group Co., Ltd.

ASH

K-Line Chart

No K-line data available

Company NameHarbin Pharmaceutical Group Co., Ltd.
Listing Date1993-06-29
Issue Price1RMB
Registered Capital251850.987610k RMB
Legal RepresentativeLu Chuanyou
Registered AddressNo. 68, Limin West Fourth Street, Limin Development Zone, Harbin City, Heilongjiang Province
IndustryChemical Pharmaceuticals
Main BusinessPurchase and sale of chemical raw materials and products (excluding hazardous and highly toxic substances); engage in import and export business within the scope approved by the Ministry of Foreign Trade and Economic Cooperation; the following are limited to branches: manufacturing of medical devices and pharmaceutical machinery (except as otherwise specified by the state), pharmaceutical commerce and drug manufacturing, production of purified water, beverages, starch, feed additives, food, cosmetics manufacturing, packaging, printing; production of abamectin technical material; production and sales of sanitary products (cleaning solutions); the following are limited to branch operations: production and sales of health food and daily chemicals; engage in direct selling in accordance with the direct selling business license.
Company ProfileHarbin Pharmaceutical Group Co., Ltd. is the first listed company in China's pharmaceutical industry and the first listed company in Heilongjiang Province. Harbin Pharmaceutical's main business covers antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biopharmaceuticals, and pharmaceutical commerce. Leading products include Cefotiam Hydrochloride for Injection, Calcium Gluconate Oral Solution, Zinc Gluconate Oral Solution, Alprostadil Injection, Hutong, High-Calcium Tablets, Shuanghuanglian Powder for Injection, Salvia Miltiorrhiza for Injection, etc. It holds 1,817 drug approvals and 178 health product approvals.

Stock Details

1. Key Indicators

  • Total Shares(W): 251850.99
  • Circulating A-Shares(W): 251850.99
  • Earnings Per Share(RMB): 0.1300
  • Net Assets Per Share(RMB): 2.2465
  • Operating Revenue(W RMB): 1202125.62
  • Total Profit(W RMB): 48103.91
  • **Net Profit Attributable to Parent(W RMB) **: 32859.45
  • Net Profit Growth Rate(%): -35.35
  • Weighted Return on Equity(%): 5.9600
  • Operating Cash Flow Per Share(RMB): -0.1330
  • Undistributed Profit Per Share(RMB): 1.1729
  • Capital Reserve Per Share(RMB): 0.2634

2. Main Business

The main business covers:

  • Pharmaceutical R&D and Manufacturing
  • Wholesale and Retail Business

3. Company Basic Information

  • Company Name: Harbin Pharmaceutical Group Co., Ltd.
  • Listing Date: 1993-06-29
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 68, Limin West Fourth Street, Limin Development Zone, Harbin City, Heilongjiang Province
  • Website: https://www.hayao.com
  • Company Profile: The company's predecessor was Harbin Pharmaceutical Group Co., Ltd., which began its股份制改组 in 1990, converting the original company's net assets and sponsor investments into 3.7528 million state shares with a face value of 50 yuan. After the initial public offering in February of the same year, the total shares reached 5.0528 million. On November 25, 1991, the shares were split into 252.64 million shares with a face value of 1 yuan per share. This total number of shares remained unchanged until listing. The 1996 profit distribution plan has been implemented, with the ex-rights date being April 24, 1997.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Harbin Pharmaceutical Group Co., Ltd. General Legal Person 117323.70 46.58
2 China Securities Investor Protection Fund Co., Ltd. General Legal Person 5572.51 2.21
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 2414.57 0.96
4 Southern China Securities 1000 ETF Fund 1381.61 0.55
5 Harbin Tianxiang Weiye Investment Co., Ltd. General Legal Person 1170.00 0.46
6 Xiamen Fucheng Financing Guarantee Co., Ltd. General Legal Person 850.00 0.34
7 ChinaAMC China Securities 1000 ETF Fund 821.33 0.33
8 GF China Securities 1000 ETF Fund 631.56 0.25

5. Concept Sectors

  • Baby & Child Concept
  • Elderly Care Concept
  • Gene Concept
  • Vitamins
  • Cross-border E-commerce
  • Generic Drugs
  • Industrial Hemp
  • Hepatitis Concept
  • Innovative Drugs
  • DeepSeek

Remarks

  • Data update date: 2025-10-24
  • Data source: Public Market Information